According to the results of our evaluation of MM cases that excluded t(14;16)-positive cases and cases not evaluated for genetic/cytogenetic abnormalities, good responders to Bd therapy expressed more NCAM than did poor responders, and the differences in NCAM expression between the two groups showed a trend towards a difference.
← all excerpts
Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma.
1
—
—